Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072600 | 0.84 | KDR (0.55) | RAF1BRAFMAPK14 | |
| SCHEMBL6072019 | 0.77 | KDR (0.53) | RAF1BRAFMAPK14 | |
| SCHEMBL14553221 | 0.77 | HRH3 (0.44) | HRH3DRD2DRD4BRAF | |
| SCHEMBL3183236 | 0.76 | DRD2 (0.47) | HRH3DRD2DRD4LCK | |
| SCHEMBL4369342 | 0.75 | PARP10 (0.54) | CYP4F2CYP4A11RAF1P2RX3BRAF | |
| SCHEMBL30832847 | 0.75 | DRD2 (0.50) | HRH3DRD2DRD4 | |
| SCHEMBL177841 | 0.75 | PARP10 (0.54) | RAF1P2RX3BRAFOPRK1KCNH2 | |
| SCHEMBL23913769 | 0.74 | P2RX3 (0.53) | HRH3RAF1P2RX3 | |
| SCHEMBL29757282 | 0.74 | P2RX3 (0.53) | HRH3RAF1P2RX3 | |
| SCHEMBL6273015 | 0.74 | RAF1 (0.50) | HRH3RAF1P2RX3BRAFOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241149-A1 | Chemical compounds | ADAMS JERRY L | 2006-10-26 | — | — | US | disclosed |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1581514-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004043379-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241149-A1 | Chemical compounds | CHKB, MAP3K20, MAP3K6 | HRH3 854/4885CYP4F2 801/4885CYP4A11 1161/4885 |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | HRH3 198/4885CYP4F2 116/4885CYP4A11 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.